Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05512325 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study on Gene Evolution in Glioma Under Stress Therapy

StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 27, 2022 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Dec 31, 2024 to Dec 31, 2025v2 Show 4 more changesShow less
    • Start date: Aug 17, 2022 to Dec 17, 2022
    • Trial status: Recruiting to Not Yet Recruiting
    • Study completion date: Dec 31, 2025 to Dec 31, 2026
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Little is known about the evolution of genetic and epigenetic changes that occur in the progression of glioma. We inferred the evolution trajectories of matched pairs of primary tumors and progression tumor in situ fluid (TISF) based on deep whole-genome-sequencing data (ctDNA). A monocentric, Gene grouping controlled trial design was used to select patients. and to compare gene evolution of different subtypes of glioma under therapy. To predict the molecular reaction of bevacizumab treatment, clarify the mechanism of drug resistance of bevacizumab treatment.
Trial Details
NCT Number NCT05512325
Lead Sponsor Henan Provincial People's Hospital
Conditions
(from sponsor)		 Genetic Change
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov